Meldal, Morten PhD
Professor at
Carlsberg Laboratory, Copenhagen
Leading researcher
with 414 publications
ORCID:
0000-0001-6114-9018
Molecular Biology
Solid-Phase Synthesis
Peptide Synthesis
Glycoprotein Synthesis
Oligosaccharide Synthesis
Glycosylation Mechanisms
Solid-phase synthesis
Diversity-Oriented Synthesis
Cleavage (geology)
Protein Glycosylation
Glycosylation
Morten Meldal graduated as PhD, 1986 at DTU in carbohydrate synthesis, structure and immunology, followed by a stay in Cambridge as a postdoctoral fellow 1986. After two years as postdoctoral fellow at University of Copenhagen he joined Carlsberg Laboratory as leader of synthesis and from 2002 as Professor. He was cofounder of Combio A/S and involved in establishing Versamatrix A/S. He headed the SPOCC center (DG) for combinatorial chemistry there from 1997-2008 and in 2011 he became professor at Department of Chemistry and Director of Nano Science Center there. In 2013 he became Director of the multidisciplinary University of Copenhagen Lighthouse Center, CECB. He coauthored of more than 330 publications and is coinventor on 30 patents. The technology he developed at CECB exploits selection principles of nature to identify compounds with superior properties through computational design and combinatorial screening processes. At CECB he developed fluorescence based assays to study molecular recognition and binding, synthetic and natural enzymes and cell signaling by combinatorial solid phase technology. Many techniques are developed in house and involve the combination of novel chemistry, design of polymers, advanced mass spectrometry, cell biology and more. The research is focused around biological target proteins such as interleukins, caspases and other proteases, the cancer specific apoptosis inhibitor XIAP, melanocortin receptors involved in memory, obesity and sexual dysfunction, and disordered proteins in control of protein expression. Of particular importance is the ability to tailor biocompatible PEG-based resins in a highly controlled manner for biomolecular and cellular screening. CECB utilize Micro Particle Matrix encoding to rapidly provide information of structure / activity of combinatorial ligands. Recently the beta-bodies, powerful antibody mimetics that can be designed computationally and with high affinity and specificity were introduced and is currently subject to start-up activities.
show More
Preview
Evolution over the last 10 years of activity
Aggregated career metrics
414
Total documents
1.66
Normalized Impact
30
Highly Cited Papers (10%)
13.29
International Collab. (%)
Join now to access advanced indicators, find research partners all over the world, and benchmark your performance with peers like never before!